| DB ID | MyCo_1122 |
| Title | Noninvasive Testing and Surrogate Markers in Invasive Fungal Diseases |
| Year | 2022 |
| PMID | 35611348 |
| Fungal Diseases involved | Cryptococcosis |
| Associated Medical Condition | None |
| Genus | Cryptococcus |
| Species | spp. |
| Organism | Cryptococcus spp. |
| Ethical Statement | None |
| Site of Infection | None |
| Opportunistic invasive | None |
| Sample type | Body fluid |
| Sample source | Cerebrospinal fluid (CSF) |
| Host Group | Human |
| Host Common name | Human |
| Host Scientific name | Homo sapiens |
| Biomarker Name | BDG |
| Biomarker Full Name | 1-3-beta-D-Glucan |
| Biomarker Type | Prognostic |
| Biomolecule | Protein |
| Geographical Location | USA |
| Cohort | None |
| Cohort No. | None |
| Age Group | None |
| P Value | None |
| Sensitivity | None |
| Specificity | None |
| Positive Predictive Value | None |
| MIC | None |
| Fold Change | None |
| Pathway | None |
| Disease Introduction Mechanism | None |
| Technique | Assay |
| Analysis Method | FDA- IMMY lateral flow assays (Norman, OK, USA), FilmArray polymerase chain reaction (PCR) testing (BioFire, Salt Lake City, UT, USA), FDA- Fungitell®, Cape Cod International, Inc.; Falmounth, MA, USA, FDA-T2Candida (T2 Biosystems, Lexington, MA, USA) |
| ELISA kits | None |
| Assay Data | FDA- IMMY lateral flow assays (Norman, OK, USA), FilmArray polymerase chain reaction (PCR) testing (BioFire, Salt Lake City, UT, USA), FDA- Fungitell®, Cape Cod International, Inc.; Falmounth, MA, USA, FDA-T2Candida (T2 Biosystems, Lexington, MA, USA) |
| Validation Techniques used | FDA Approved -Lateral flow assays, ELISA, BDG Assay, PCR |
| Up Regulation Down Regulation | Positive |
| Sequence Data | None |
| External Link | None |
